Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.28 | -$1.09 | Beat |
| May 13, 2026 | -$1.20 | -$1.46 | Miss |
| Mar 12, 2026 | -$1.24 | -$1.11 | Beat |
| Nov 6, 2025 | -$1.71 | -$2.84 | Miss |
| Aug 7, 2025 | -$1.96 | -$1.76 | Beat |
| May 8, 2025 | -$1.68 | -$1.68 | Beat |